Please login to the form below

Not currently logged in
Email:
Password:

cancer drug funding

This page shows the latest cancer drug funding news and features for those working in and with pharma, biotech and healthcare.

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need. Patients with a form of skin cancer will be able to access Sanofi/Regeneron's new checkpoint inhibitor Libtayo via the NHS in England, after funding for the ... The cost-effectiveness watchdog has published guidance recommending

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... It was also shared by a student midwife who tweeted to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....